News Analysis: Steroids and Back Pain: An Uneasy Match


RANDALL KINNAIRD’S legal clients had steroids injected into their backs last summer for a wide range of reasons. Of the 25, one got three shots in a two-month period when pain never totally disappeared. Another got one as a preventive measure because she was going on a trip to Europe and was worried that cobblestones would aggravate an old injury.


Now the 25 — or their survivors — have engaged Mr. Kinnaird, one of Nashville’s leading lawyers, to sue the New England Compounding Center. Three have died, one is paralyzed, several more are still hospitalized and all suffer blinding headaches — victims of the meningitis that resulted from vials of steroid medicine contaminated by fungus.


The New England Compounding Center certainly seems deserving of its current status as the prime culprit in a tragic outbreak that has killed 32 and sickened 438. The bottles of supposedly sterile steroid medication it shipped were reportedly so tainted that white fuzz could be seen floating in some vials.


But, experts say, the now notorious Compounding Center has a nationwide network of unwitting enablers and accomplices: There are the doctors who overprescribe an invasive back-pain therapy that, in studies, has not proved useful for many of the patients who get it. And there are the patients, living in an increasingly medicalized society, who want a quick fix for life’s aches and pains.


The use of steroid injections to treat back pain has skyrocketed in the past 15 years — out of proportion to growth in the number of patients with back pain, or the aging of the population. The frequency of steroid injections dispensed to Medicare patients rose 121 percent from 1997 to 2006. Washington State found that the use of back injections grew 12.6 percent between 2006 and 2009, at a cost to the state of $56 million. Some people received more than 10 shots a year.


The increase in treatment has not led to less pain over all, researchers say, and is a huge expense at a time of runaway health costs. “There are lots of places doing lots of injections for conditions that haven’t been shown to benefit,” says Dr. Janna Friedly, a researcher at the University of Washington, who added, “Sadly, some of the patients who got meningitis were probably in that category — they did not have conditions where steroid injections were indicated.”


Studies are at best inconclusive about exactly which groups of back-pain patients are likely to benefit from steroid shots. Though some patients clearly get much-needed relief, health researchers are nearly unanimous that the treatment is vastly overused in the United States.


But Dr. Laxmaiah Manchikanti, head of the American Society of Interventional Pain Physicians, said the increasing number of spine injections was just part of “an exponential increase in all interventional techniques” and is a good thing, reflecting a better understanding of chronic pain and patients’ demands for improved pain relief.


Though doctors are still arguing, most academic researchers say there is no evidence that steroid injections are useful in easing straightforward chronic low back pain. Professional guidelines say such shots should generally not be used for back pain that is less than four to six weeks old, which studies show almost always gets better with noninvasive treatments. Although many Medicare patients get spinal injections to treat a condition called spinal stenosis, a narrowing of spaces between bones of the spine, Dr. Friedly said, shots are not used for that condition in many European countries.


Spinal injections, which can cost between $600 and $2,500, including the fees for treatment rooms, have been fostered and promoted by the rising number of pain clinics and pain specialists — mostly anesthesiologists and rehab doctors — who invest in extra training to learn procedures like spinal injections.


“There used to be only a small number of people who did this, but that’s gone way up, and reimbursement has gone up, too,” says Scott Forseen, a doctor who studies the treatment of back pain at the Georgia Health Sciences University. The number of spinal injections given in any geographical area correlates better with the number of local specialists trained in the procedure rather than the amount of back pain, Dr. Friedly says. There is an old saying in medicine: “When you go to Midas, you get a muffler.”


The shots — which may include a steroid and an anesthetic — are often dispensed at for-profit pain clinics owned by the physicians holding the needle. “There’s a lot of concern about perverse financial incentive,” Dr. Friedly added.


Mr. Kinnaird’s clients got their injections at the St. Thomas Outpatient Neurosurgery Clinic, a limited-liability corporation half owned by doctors, which occupied a floor of one of Nashville’s major hospitals. It gave 5,000 injections a year, or about 20 each business day, and epidural steroid injections are listed on its Web site as its “top procedure.”


Since guidelines for injections are being disputed among doctors’ groups, it is hard in most cases to say if a particular patient should or should not have been offered an injection, says Marc Lipton, a Michigan attorney who is representing more that 20 patients with fungal meningitis. Though he believes that steroid shots are overused, he says many of the patients he represents were treated appropriately, for example, receiving an injection for pain from a herniated disc in an attempt to stave off back surgery. He and other lawyers are, for now, targeting the Compounding Center in product liability lawsuits.


But, says Dr. Forseen: “You have to use injections selectively, and selectivity has gone way down. In some places, people get injections because they’ve walked in the door.”


Patients have proved eager consumers of the new medical offering, desirous of a quick cure rather than waiting the weeks or months for the normal healing process to occur.


Mr. Kinnaird, the lawyer, says: “If I hurt my back in the ’70s, my doctor would say, go to the beach, get a few beers, relax, you’ll be fine. Now if you hurt your back, you go to the doctor and right away there’s an M.R.I., and they need to fix something. Maybe you should take an injection.”


And steroid shots are not a cure-all, even for the conditions for which doctors agree an attempt is worthwhile: low back pain accompanied by signs of nerve injury like tingling or weakness in a leg. One-third of such patients will get better, one-third will show some improvement and some will show no improvement at all, Dr. Forseen said.


When Oregon’s Health Evidence Review Commission earlier this year explored narrowing reimbursement for injections to certain conditions, it got an earful of public comment from groups like the International Spine Intervention Society.


“Obviously they are not utilizing the literature correctly,” said Dr. Manchikanti, adding that attempts to limit the shots were motivated in part by an effort to control costs and by competition from other medical specialties.


Private insurers vary considerably in coverage for the procedure, though some will pay after two weeks of back pain.


Back pain is, of course, a debilitating condition. And modern medicine has produced some miraculous cures. But from now on when doctors and patients are tempted to say “what’s the harm in trying an injection” to dispense with a nagging back — they will be more aware of just how big the risk can be.


A physician and a reporter for The New York Times.



Read More..

Black Friday: A survival guide



Shopping












The plan | The numbers | The gear | The strategy | The apps | The start






Black Friday, the most buzzed-about shopping day of the year, is starting even earlier this holiday season as retailers try to get a jump on the competition.

The official kickoff to the Christmas shopping rush, the day after Thanksgiving brings out millions of bargain hunters looking to score new tablets, flat-panel TVs, clothes and toys. Last year retailers raked in an estimated $11.4 billion on Black Friday, up 6.6% from 2010.

This year, major retailers including Wal-Mart and Toys R Us are opening their doors as early as 8 p.m. on Thanksgiving Day. That’s too bad for store employees, but good news if you’re a shopaholic who doesn’t mind hitting the shops before the turkey has cooled.

For those of you who are planning to brave the crowds, whether you’re a first-timer or a seasoned veteran, here’s a guide to surviving the Black Friday rush.


-- Andrea Chang



























Photo credit: Francine Orr / Los Angeles Times










Photo credit: Mark Boster / Los Angeles Times










Photo credit: Mark Boster / Los Angeles Times










Photo credit: Brian van der Brug / Los Angeles Times










Photo credit: Seong Joon Cho / Bloomberg










Photo credit: Associated Press






Read More..

Veteran L.A. County sheriff's deputy charged with murder









After spending much of his life putting people behind bars, a veteran L.A. County sheriff's deputy stood in handcuffs Thursday, charged with gunning down a former neighbor who apparently got into a fight with his son.


Francisco Gamez, 41, is accused of shooting Armando "Cookie" Casillas, a well-known figure in his blue-collar neighborhood in Sylmar.


Gamez was off duty, sitting in his car, when he allegedly fired two shots on the night of June 17, killing Casillas and narrowly missing a second man, prosecutors said.





Gamez, a 17-year veteran who worked as a detective in West Hollywood, was allegedly furious over a fight between his 20-year-old son and Casillas, 38, prosecutors said. The younger Gamez had called his father to the scene, authorities said.


Casillas was later found by relatives lying near his home, and died later at Providence Holy Cross Medical Center.


Gamez was removed from duty in July after witnesses and evidence tied the detective to the slaying, authorities said. He was arrested Wednesday and led handcuffed from his San Fernando home by his former co-workers.


On Thursday he was formally charged with murder, attempted murder and discharging a firearm from an occupied vehicle. Gamez could face 75 years to life in prison if convicted of all charges.


In court, where he stood handcuffed in a plexiglass cage, sheriff's deputies peeked into the room to gawk at their former colleague. Sheriff Lee Baca described the whole thing as "deeply disturbing."


Gamez is being held on $4-million bail.


On Beaver Street in Sylmar, where the shooting occurred, Casillas' photo sat in a frame in the midst of a makeshift memorial, along with a cross and a potted plant with U.S. and Mexican flags and candles.


"He was a sweetheart, and very generous," said Patsy Telles-Cabrera, who lived across the street from Casillas for years. "He would check in on my parents." She left a box of chocolates at the growing shrine.


"It never should have happened," said one neighbor. "This is a family neighborhood."


sam.quinones@latimes.com


richard.winton@latimes.com


Times staff writer Wesley Lowery contributed to this report.





Read More..

Ruckus Wireless prices IPO at high end of range: market source
















(Reuters) – WiFi products maker Ruckus Wireless Inc priced its initial public offering at $ 15 per share, the high end of its expected price range, a market source told Reuters.


The company, which is backed by Google Inc‘s Motorola Mobility LLC and venture capital firm Sequoia Capital, raised $ 126 million by selling 8.4 million shares.













Ruckus offered 7 million shares while selling shareholders, including Telus Corp, offered 1.4 million shares.


The Sunnyvale, California-based company, which makes wireless LAN products for both indoor and outdoor use, competes with Meru Networks Inc and Aruba Networks Inc.


The company’s customers include Time Warner Cable Inc, Towerstream Corp, Tikona Digital Networks and Bright House Networks.


Goldman Sachs & Co and Morgan Stanley are the lead underwriters to the offering.


The company’s shares are expected to begin trading on the New York Stock Exchange on Friday under the ticker symbol “RKUS”.


(This story was fixed to correct description of Sequoia Capital to venture capital firm in paragraph 2)


(Reporting by Sharanya Hrishikesh and Ashutosh Pandey in Bangalore; Editing by Sriraj Kalluvila)


Wireless News Headlines – Yahoo! News



Read More..

4 Latin Grammys to Jesse & Joy, Juanes wins too

LAS VEGAS (AP) — Mexican brother-sister duo Jesse & Joy and their pop hit "Corre!" ran away with four awards at the 13th Annual Latin Grammys, but Colombian rockero Juanes danced away with the award for best album for "MTV Unplugged" Thursday night.

"What a great joy. Thank God, and all the fans," Juanes said as he dragged Dominican mereguero Juan Luis Guerra, who produced the album, to the stage to accept the mini-gramaphone for best album at the close of the ceremony.

The winner for best new artist, the Mexican DJ trio 3ball MTY, threw down beats with America Sierra and Sky Blu of LMFAO. Pitbull performed "Don't Stop the Party" with dancers in gold spangled bikinis and hot pants. Juanes jammed with legendary guitarist Carlos Santana.

Hosted by actors Cristian De La Fuente and Lucero, the ceremony attracted super-stars from across the world and from dozens of Latin musical genres to the Mandalay Bay Events Center. Just like at a big family party, new faces shared the spotlight with older generations, and traditional styles mixed with electronica and Vegas dancers on stage.

Traditional Mexico met Las Vegas in a colorful number featuring Oaxaca native Lila Downs, Afro-Colombian singer Toto la Momposina and dancers in regional costumes, Carnival masques and skeleton makeup.

Michel Telo, the Brazilian sertanejo or country music singer, performed his hit, "Ai si eu te pego,"with Blue Man Group. Bachata heartthrob Prince Royce sang with veteran Mexican singer-songwriter Joan Sebastian. But the applause was also strong for the 1980s hit, "Yo No Te Pido la Luna," a duet between Spaniard Sergio Dalma and Mexican singer Daniela Romo, sporting a short silver hairdo following her bout with breast cancer.

Jesse & Joy also won for best contemporary pop vocal album for "Con Quien se Queda el Perro" and best short video for "Me vow."

"Thanks to people like Juanes and Juan Luis Guerro who have inspired us. Love and peace," Jesse said.

Guerra, who came into the ceremony as the leading nominee with six bids, won producer of the year for Juanes' album "MTV Unplugged."

Guerra performed "En el Cielo No Hay Hospital," which brought the audience to its feet to dance, and for a standing ovation.

Puerto Rican reggaeton singer Don Omar and Uruguayan alt rockers Cuarteto de Nos won two Latin Grammys each.

Downs won best folkloric album for "Pecados y Milagros." Colombian singer Fonseca won for best tropical fusion album, and Los Tucanes de Tijuana won best norteno album for "365 Dias," the narco-corrido band's 32nd album.

Milly Quezada brought home two statuettes, including best contemporary tropical album for "Aqui estoy yo."

"Long live merengue! Long live the Dominican Republic!" she said as she accepted the award. She also thanked Guerra, who helped produce the album.

Cuban-American jazz trumpeter Arturo Sandoval won three Latin Grammys, two for "Dear Diz (Every Day I Think of You)," but said these awards was just exciting as his first.

"The emotion is the same because one puts the same effort into each recording and the fact that the work is received well and respected by the public is very satisfying," he said.

The Latin Grammy celebration kicked off Wednesday with a tribute to Person of the Year winner, Caetano Veloso, one of the founders of the Tropicalismo movement.

The Brazilian singer, composer and activist sang in Spanish and Portuguese before Pitbull and Sensato closed with "Crazy People."

The event was broadcast live on Univision.

Interactive: http://hosted.ap.org/interactives/2012/latin-grammys/

Read More..

Change Rattles Leading Health-Funding Agency





Major changes erupted at one of the world’s leading health-funding agencies Thursday as it hired a new director, dismissed the inspector general who had clashed with a previous director and announced a new approach to making grants.







Alex Wong/Getty Images

Dr. Mark Dybul, who led the President's Emergency Plan for AIDS Relief, in 2007.








Dr. Mark Dybul, the Bush administration’s global AIDS czar who was abruptly dismissed when President Obama took office, was named the new executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.


Dr. Dybul, who was selected over candidates from Canada, Britain and France, was backed by the United States, which donates about a third of the fund’s budget, and by Bill Gates, who helped the fund through a cash crisis earlier this year.


He is respected by many AIDS activists in the United States, though there is some lingering controversy about his time in the Bush administration related to abstinence policies and anti-prostitution pledges imposed by conservative lawmakers as well as concerning strict licensing requirements for generic drugs.


The fund, which is based in Geneva and has given away more than $20 billion since its founding in 2002, has been in crisis for more than a year. Some donors shied away after widely publicized corruption scandals, while others, notably Mr. Gates, said the scandals were exaggerated and increased donations.


Its last executive director, Dr. Michel Kazatchkine, quit in January after the day-to-day management duties of his job were given to a Brazilian banker, Gabriel Jaramillo, who was charged with cutting expenses.


By some accounts, 40 percent of the employees soon left, although Seth Faison, a fund spokesman, said the total number of employees declined by only 8 percent. The fund also dismissed its inspector general, John Parsons, on Thursday, citing unsatisfactory work.


Mr. Parsons and Dr. Kazatchkine had privately clashed. Mr. Parsons’s teams aggressively pursued theft and fraud, and found it in Mali, Mauritania and elsewhere. But the total amount stolen — $10 million to $20 million — was relatively small, and aides to Dr. Kazatchkine said the fund cut off those countries and sought to retrieve the money. The aides claimed that Mr. Parsons, who reported only to the board, went to news outlets and left the impression that the fund was covering up rampant theft.


The fuss scared off some donor countries that were already looking for excuses to cut back on foreign aid because of the global economic crisis.


Mr. Parsons did not return messages left for him Thursday.


Dr. Dybul’s appointment was welcomed by the United Nations AIDS program, the Bill and Melinda Gates Foundation, the Elizabeth Glaser Pediatric AIDS Foundation, Malaria No More and Results.org, an anti-poverty lobbying group. By contrast, Jamie Love, an American advocate for cheaper AIDS drugs who works in Washington and Geneva, said he expected Dr. Dybul “to protect drug companies.”


The fund also announced a new application process, which it said would be faster and focus more on the hardest-hit countries rather than all 150 that received some help in the past.


In an interview, Dr. Dybul said he felt the fund was “on a strong forward trajectory” after changes were put in place in the last year by Mr. Jaramillo, and now would focus on “hard-nosed implementation of value for money.”


Both the President’s Emergency Plan for AIDS Relief and the fund spend billions, but in different ways.


The fund supports projects proposed by national health ministers and then hires local auditors to make sure the money is not wasted or stolen. Pepfar usually gives grants to American nonprofit groups or medical schools and lets them form partnerships with hospitals or charities in the affected countries.


The conventional wisdom is that the Global Fund’s model is more likely to win the cooperation of government officials but more vulnerable to corruption — and also spends less on salaries and travel for American overseers.


Dr. Kazatchkine said he did not expect Dr. Dybul to “Pepfarize” the Global Fund.


“I hope that, after a year of turbulence, the fund finds the serenity needed to move forward again,” he said.


Read More..

JPMorgan's California energy dealings draw more fire









State and federal energy regulators moved on two fronts against the giant investment bank JPMorgan Chase & Co. over its dealings in the California electricity market.

On Wednesday, the Federal Energy Regulatory Commission hit Morgan's electricity-trading unit with one of the most stringent penalties in its arsenal, barring it from selling electricity in California's auction-based market for six months starting in April.

The ruling, which may deprive Morgan of millions of dollars in profits in California, stemmed from FERC's conclusion that JPMorgan Ventures Energy Corp. had misled the agency in its investigation of alleged overcharges to the California Independent System Operator, which runs much of the state's wholesale power grid.








Meanwhile, the ISO moved Thursday to stop Morgan from blocking the upgrade of two Huntington Beach power plants considered key to keeping air conditioners humming next summer in Southern California. Morgan could not be reached for comment.

The operator of California's far-flung power grid filed a petition with federal regulators, accusing Morgan of raising legal obstacles to getting the plants working in time to avoid possible brownouts and rolling blackouts when the temperatures climb.

The shoreline facilities, currently not in use, are needed to help make up for the loss of more than 2,000 megawatts of power caused by the shutdown for safety reasons of both reactors at Southern California Edison's San Onofre Nuclear Generating Station.

Several power plants in Huntington Beach are owned by AES Corp. Two of them currently supply power to Morgan. But it is two other plants there, currently not operating, that the state wants to upgrade.

But the ISO says AES is balking, saying Morgan doesn't want to go along with the upgrade. The state is trying to force Morgan and AES to go ahead.

Grid operators want FERC to rule that JPMorgan's consent is not needed to retrofit the Huntington Beach power plants. The retrofit is essential to maintain sufficiently high voltage in transmission lines to meet peak summertime demand.

"The inability to resolve the consent issue in time to allow construction to commence in early 2013 could leave Southern California exposed to reliance on a widespread load-shedding scheme in the summer of 2013," state officials warned the commission.

The state agency's petition was submitted one day after federal energy regulators suspended JPMorgan Ventures after finding that the energy firm had provided false data and omitted important information during the federal investigation. It is reviewing state allegations that the firm hit utilities with excessive charges of as much as $73 million in 2011 and the beginning of this year.

Of that, the state has recovered about $20 million in overcharges, said Stephanie McCorkle, a spokeswoman for the state power grid operator.

The suspension was ordered to begin April 13 of next year. The delay was aimed at giving the grid managers sufficient time to contract for new power deliveries to ensure the lights stay on across the state.

JPMorgan Ventures is one of several energy-trading firms that buy and sell power nationally and play a key role in delivering electricity to states when demand is high and supplies are short.

The firm fought the suspension and told the commission in October that the company's actions were "inadvertent mistakes" and said that suspending its trading authority would be an "unjustified reaction to unintentional, good-faith mistakes, misunderstandings and miscommunications."

marc.lifsher@latiimes.com





Read More..

L.A. County sheriff's deputy held in fatal off-duty shooting









A veteran Los Angeles County sheriff's deputy was arrested Wednesday for allegedly shooting and killing a man in Sylmar while off-duty in June, authorities said.

The deputy, Francisco Gamez, 41, has been with the department for 17 years and was last working as a station detective in West Hollywood.

Law enforcement sources told The Times that the deputy's son got into a dispute with another person. The son, they said, called his father to the scene. The deputy allegedly drove up soon after and exchanged words before opening fire from inside his car, striking one man, the sources said.





He then allegedly drove a short distance before shooting at a second person, added the sources, who asked for anonymity because the investigation is ongoing.

That person was not injured, according to authorities.

The other victim, Armando Casillas, 38, was taken to a hospital, where he was pronounced dead from a gunshot wound to the chest just before midnight on June 17.


FOR THE RECORD:
An earlier version of this article misspelled the victim's first name as Armondo.

Neighbors said Gamez and Casillas lived a block apart.

In August, a person who identified himself as the victim's brother commented on the website of the Los Angeles Times, saying he suspected a deputy was responsible.

"We think he is a L.A. COUNTY SHERIFF," the comment stated. "The reason we think he is a Sheriff is that he shouted to my Brother "L.A. COUNTY SHERIFF WHERE YOU FROM" as if the sheriff was in a gang."

The person who wrote the comment could not be reached Wednesday evening.

At the time of the killing, authorities said the victim got into an argument with an unknown person. At some point, the other person left the area only to return and shoot Casillas in a drive-by, authorities said then. Now they are saying that the shooter was not the same person who initially got into the argument.

LAPD officers arrested Gamez on suspicion of murder, attempted murder and use of a firearm in the commission of a felony. He was booked into the LAPD's 77th Street station Wednesday in lieu of $4-million bail, officials said. He has not been charged.

Casillas' sister said that the family was thankful for the arrest, but that they were not prepared to discuss the events that led to the fatal shooting.

In a statement, Sheriff Lee Baca called the incident "deeply disturbing."

His spokesman Steve Whitmore said the department placed Gamez on leave July 3 after learning from the LAPD about the investigation.

"He's been stripped of all law enforcement power," Whitmore said. "It casts a pall over the scores and scores of deputy sheriffs that every day do their job."

robert.faturechi@latimes.com

richard.winton@latimes.com

Times staff writer Andrew Blankstein contributed to this report.





Read More..

Erdrich wins National Book Award for fiction

NEW YORK (AP) — The National Book Awards on Wednesday honored both longtime writers and new authors, from Louise Erdrich for "The Round House" to Katherine Boo for her debut work, "Beyond the Beautiful Forevers."

Erdrich, 58, has been a published and highly regarded author for nearly 30 years but had never won a National Book Award until being cited Wednesday for her story, the second of a planned trilogy, about an Ojibwe boy and his quest to avenge his mother's rape. A clearly delighted and surprised Erdrich, who's part Ojibwe, spoke in her tribal tongue and then switched to English as she dedicated her fiction award to "the grace and endurance of native people."

The works of two other winners also centered on young boys — Boo's for nonfiction, and William Alexander's fantasy "Goblin Secrets," for young people's literature. David Ferry won for poetry.

Boo's book, set in a Mumbai slum, is the story of a boy and his harsh and illuminating education in the consequences of crime or perceived crime. The author, a Pulitzer Prize-winning journalist currently on staff with The New Yorker, said she was grateful for the chance to live in a world she "didn't know" and for the chance to tell the stories of those otherwise ignored. She praised a fellow nominee and fellow Pulitzer-winning reporter, the late Anthony Shadid, for also believing in stories of those without fame or power.

Boo was chosen from one of the strongest lists of nonfiction books in memory, from the fourth volume of Robert Caro's Lyndon Johnson series to Shadid's memoir "House of Stone" and Anne Applebaum's "House of Stone." Finalists in fiction, which in recent years favored lesser known writers, included such established names as Dave Eggers and Junot Diaz. Publishers have been concerned that the National Book Awards have become too insular and are considering changes, including expanding the pool of judges beyond writers.

Winners, chosen by panels of their peers, each will receive $10,000.Judges looked through nearly 1,300 books.

Ferry is a year older than one of the night's honorary recipients, Elmore Leonard. Ferry, 88, won for "Bewilderment: New Poems and Translations," a showcase for his versatile style. He fought back tears as he confided that he thought there was a chance for winning because he "was so much older" than the other nominees. Attempting to find poetry in victory, he called the award a "pre-posthumous" honor.

Alexander quoted fellow fantasy writer Ursula K. Le Guin in highlighting the importance of stories for shaping kids' imaginations and making the world a larger place than the one they live in.

"We have to remember that," Alexander said.

The ceremony was hosted by commentator-performer Faith Salie and went smoothly even though Superstorm Sandy badly damaged the offices of the award's organizer, the National Book Foundation, whose staffers had to work with limited telephone and mail access.

Honorary prizes were given to Leonard and New York Times publisher and chairman Arthur O. Sulzberger Jr.

Read More..

Alzheimer’s Tied to Mutation Harming Immune Response





Alzheimer’s researchers and drug companies have for years concentrated on one hallmark of Alzheimer’s disease: the production of toxic shards of a protein that accumulate in plaques on the brain.




But now, in a surprising coincidence, two groups of researchers working from entirely different starting points have converged on a mutated gene involved in another aspect of Alzheimer’s disease: the immune system’s role in protecting against the disease. The mutation is suspected of interfering with the brain’s ability to prevent the buildup of plaque.


The discovery, researchers say, provides clues to how and why the disease progresses. The gene, known as TREM2, is only the second found to increase Alzheimer’s risk substantially in older people.


“It points very specifically to a potential metabolic pathway that you could intervene in to change the course of Alzheimer’s disease,” said William Thies, chief medical and scientific officer of the Alzheimer’s Association.


Much work remains to be done before scientists understand precisely how the newly discovered gene mutation leads to Alzheimer’s, but already there are some indications from studies in mice. When the gene is not mutated, white blood cells in the brain spring into action, gobbling up and eliminating the plaque-forming toxic protein, beta amyloid. As a result, Alzheimer’s can be staved off or averted.


But when the gene is mutated, the brain’s white blood cells are hobbled, making them less effective in their attack on beta amyloid.


People with the mutated gene have a threefold to fivefold increase in the likelihood of developing Alzheimer’s disease in old age.


The intact gene, says John Hardy of University College London, “is a safety net.” And those with the mutation, he adds, “are living life without a safety net.” Dr. Hardy is lead author of one of the papers.


The discovery also suggests that a new type of drug could be developed to enhance the gene’s activity, perhaps allowing the brain’s white blood cells to do their work.


“The field is in desperate need of new therapeutic agents,” said Alison Goate, an Alzheimer’s researcher at Washington University in St. Louis who contributed data to Dr. Hardy’s study. “This will give us an alternative approach.”


The fact that two research groups converged on the same gene gives experts confidence in the findings. Both studies were published online Wednesday in The New England Journal of Medicine. “Together they make a good case that this really is an Alzheimer’s gene,” said Gerard Schellenberg, an Alzheimer’s researcher at the University of Pennsylvania who was not involved with the work.


The other gene found to raise the odds that a person will get Alzheimer’s, ApoE4, is much more common and confers about the same risk as the mutated version of TREM2. But it is still not clear why ApoE4, discovered in 1993, makes Alzheimer’s more likely.


Because the mutations in the newly discovered gene are rare, occurring in no more than 2 percent of Alzheimer’s patients, it makes no sense to start screening people for them, Dr. Thies said. Instead, the discovery provides new clues to the workings of Alzheimer’s disease.


To find the gene, a research group led by Dr. Kari Stefansson of deCODE Genetics of Iceland started with a simple question.


“We asked, ‘Can we find anything in the genome that separates those who are admitted to nursing homes before the age of 75 and those who are still living at home at 85?’ ” he said.


Scientists searched the genomes of 2,261 Icelanders and zeroed in on TREM2. Mutations in that gene were more common among people with Alzheimer’s, as well as those who did not have an Alzheimer’s diagnosis but who had memory problems and might be on their way to developing Alzheimer’s.


The researchers confirmed their results by looking for the gene in people with and without Alzheimer’s in populations studied at Emory University, as well as in Norway, the Netherlands and Germany.


The TREM2 connection surprised Dr. Stefansson. Although researchers have long noticed that the brain is inflamed in Alzheimer’s patients, he had dismissed inflammation as a major factor in the disease.


“I was of the opinion that the immune system would play a fairly small role, if any, in Alzheimer’s disease,” Dr. Stefansson said. “This discovery cured me of that bias.”


Meanwhile, Dr. Hardy and Rita Guerreiro at University College London, along with Andrew Singleton at the National Institute on Aging, were intrigued by a strange, rare disease. Only a few patients had been identified, but their symptoms were striking. They had crumbling bones and an unusual dementia, sclerosing leukoencephalopathy.


“It’s a weird disease,” Dr. Hardy said.


He saw one patient in her 30s whose brain disease manifested in sexually inappropriate behavior. Also, her bones kept breaking. The disease was caused by mutations that disabled both the copy of TREM2 that she had inherited from her mother and the one from her father.


Eventually the researchers searched for people who had a mutation in just one copy of TREM2. To their surprise, it turned out that these people were likely to have Alzheimer’s disease.


They then asked researchers around the world who had genetic data from people with and without Alzheimer’s to look for TREM2 mutations.


“Sure enough, they had good evidence,” Dr. Hardy said. The mutations occurred in one-half of 1 percent of the general population but in 1 to 2 percent of patients with Alzheimer’s disease.


“That is a big effect,” Dr. Hardy said.


Read More..